First Tracks Biotherapeutics Inc. (TRAX:NASDAQ) closed at $53.27 on November 11, 2026, up 1.81% on the day. The stock trades 2.8% below its 52-week high of $54.78 and 261.9% above its 52-week low of $14.72. Over the past year, it gained 175.4%. First Tracks Biotherapeutics Inc. is part of the Health Care sector.
In 152 trading sessions since April 7, 2026, TRAX closed higher on 77 days (51%). Its best day was July 9, 2026 (+55.99%) and its worst was April 20, 2026 (-17.37%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 3 times.
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis ("RA"), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease ("CeD") and eosinophilic esophagitis ("EoE"), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
Find more stocks like TRAX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.